Roche’s Rituxan outperforms MMF in pemphigus vulgaris study

Roche announces data from the Phase III PEMPHIX study evaluating the efficacy and safety of rituximab compared to MMF in adults with moderate to severe PV. Credit: F. Hoffmann-La Roche Ltd.



  • Rituxan